Abstract: Background and purpose: For patients with relapsed or refractory B-cell lymphoma, conventional therapy is not effective. Researching new treatment technology to improve prognosis is imminent. Chimeric antigen receptor T-cell (CAR-T) technology has high safety and remission rate in B-cell lymphoma. The incidence rates of cytokine release syndrome (CRS) and neurological toxicity in the treatment of B-cell lymphoma with CAR-T were investigated in this study, so as to provide guidance for CAR-T in the treatment of lymphoma. Methods: Following comprehensive retrieval of PubMed database and the Cochrane Library database in English literature, a quantitative and comprehensive analysis was conducted for ten articles regarding CAR-T in the treatment of B-cell lymphoma that were published from the establishment of the databases to Jan, 2018. The incidence rate was used as the outcome. According to the difference of toxicity, Meta-analysis of the incidence rate was performed. Results: The total incidence rate of CRS in B-cell lymphoma treated with CAR-T was 57% (95% CI: 0.25-0.90), while the total incidence rate of neurological toxicity in B-cell lymphoma treated with CAR-T was 48% (95% CI: 0.30-0.66). Conclusion: The incidence rates of CRS and neurological toxicity in B-cell lymphoma treated with CAR-T are both high.

Key words: Lymphoma, B-cell, Toxicity, Meta-analysis, Chimeric antigen receptor T-cell, Incidence rate